Metfendrazine

Metfendrazine
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 1-methyl-1-(1-methyl-2-phenyl-ethyl)hydrazine;
CAS Number	3734-26-7 ;
PubChem CID	19516;
ChemSpider	18390;
UNII	A52QTC656T;
CompTox Dashboard (EPA)	DTXSID701257364 ;
Chemical and physical data
Formula	C10H16N2
Molar mass	164.252 g·mol−1

Metfendrazine (HM-11, MO-482), also known as methphendrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class.^[1]^[2] It was investigated as an antidepressant, but was never marketed.

References

^ Miquel, J.; Mijan, C. D. (1962). "Metfendrazine, a new inhibitor of monoamine oxidase". Arch. Inst. Farmacol. Exp. (Madrid). 14: 47–59.
^ Kothari NJ, Saunders JC, Kline NS, Griffen JA (October 1960). "A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics". The American Journal of Psychiatry. 117 (4): 358–60. doi:10.1176/ajp.117.4.358. PMID 13753478.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[Metfendrazine,_a_new_inhibitor_of_monoamine_oxidase-1] Miquel, J.; Mijan, C. D. (1962). "Metfendrazine, a new inhibitor of monoamine oxidase". Arch. Inst. Farmacol. Exp. (Madrid). 14: 47–59.

[pmid13753478-2] Kothari NJ, Saunders JC, Kline NS, Griffen JA (October 1960). "A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics". The American Journal of Psychiatry. 117 (4): 358–60. doi:10.1176/ajp.117.4.358. PMID 13753478.

[1]

[2]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

See also

References